INS and diabetes mellitus: With rapid advances in drug discovery, new drugs such as SGLT‐2 (sodium‐dependent glucose transporters) and α‐glucosidase inhibitors are commercially available along with conventional drugs such as insulin, sulfonylureas, biguanides, and thiazolidinediones.[6] However, the increase in the number of diabetes patients, as predicted by IDF, underscores the fact that current therapeutic approaches for diabetes are not effective.[7] Therefore, there is an urgent need to develop new drugs as well as effective drug delivery strategies with more precise efficacies and fewer side effects.